CoMind, a London-based startup developing a non-invasive yet accurate solution for patient brain monitoring, pulled in $102.5 million in funding to advance its first product, CoMind One. The company’s investors include Plural, which led the round, alongside Angelini Ventures, LocalGlobe and others.
The company aims to make critical information about cerebral blood flow, cerebral autoregulation and intracranial pressure more easily and continually available from a patient’s bedside. Its goal is to provide an alternative to invasive measurement methods that involve drilling through a patient’s skull and less accurate non-invasive methods that could compromise treatment.
The fresh capital will enable CoMind to advance regulatory approval for CoMind One. The company will also invest in completing additional clinical trials, expanding its team and establishing manufacturing partnerships.
